¼¼°èÀÇ HCS(High Content Screening) ½ÃÀå
High Content Screening (HCS)
»óǰÄÚµå : 1514185
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 183 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,163,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,489,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ HCS(High Content Screening) ½ÃÀåÀº 2030³â±îÁö 22¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 12¾ï ´Þ·¯·Î Æò°¡µÈ ¼¼°èÀÇ HCS(High Content Screening) ½ÃÀåÀº ºÐ¼® ±â°£ 2023³âºÎÅÍ 2030³â±îÁö CAGR 9.1%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 22¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ HCS Àåºñ´Â CAGR 9.3%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 10¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. HCS ¼Ò¸ðǰ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 8.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 3¾ï970¸¸ ´Þ·¯, Áß±¹Àº CAGR 12.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ HCS(High Content Screening) ½ÃÀåÀº 2023³â 3¾ï 970¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 4¾ï 9,270¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ 2023³âºÎÅÍ 2030³â±îÁö CAGRÀº 12.2%·Î Àü¸ÁµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 6.0%¿Í 7.2%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 7.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ HCS(High Content Screening) ½ÃÀå-ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

HCS(High Content Screening)Àº ½Ç½Ã°£À¸·Î ¼¼Æ÷ °úÁ¤ÀÇ »ó¼¼ÇÑ °üÂûÀ» °¡´ÉÇÏ°Ô Çϰí, ƯÈ÷ ¸ÂÃãÇü ÀÇ·áÀÇ °³¹ßÀ» °­È­ÇÔÀ¸·Î½á »ý¹°ÇÐ ¿¬±¸ ¹× â¾à ºÐ¾ß¿¡ Çõ¸íÀ» °¡Á®¿À°í ÀÖ½À´Ï´Ù. HCS´Â ¼¼Æ÷¿¡ ´ëÇÑ ´Ù¾çÇÑ È­ÇÕ¹°ÀÇ ¿µÇâÀ» Á¶»çÇϱâ À§ÇØ °í±Þ À̹Ì¡ ¹× ºÐ¼® ±â¼úÀ» Ȱ¿ëÇÏ¿© ºÐ¸®µÈ ¼¼Æ÷¸¦ »ç¿ëÇÏ´Â ±âÁ¸ÀÇ ¹æ¹ý·ÐÀ» ÈξÀ ¶Ù¾î³Ñ´Â ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ ±â¼úÀº ƯÈ÷ ¿À°¡³ëÀÌµå ¹× Á¶Á÷ ÀýÆí°ú °°Àº »ì¾ÆÀÖ´Â ´Ù¼¼Æ÷ ±¸Á¶¿¡ Àû¿ëÇÔÀ¸·Î½á Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ ¼¼Æ÷ ¼öÁØ¿¡¼­ÀÇ ¹Ì¹¦ÇÑ °üÂûÀº °Ç°­°ú Áúº´ »óŸ¦ Ư¡À¸·Î ÇÏ´Â ¼¼Æ÷ÀÇ ¿ªÇÐÀ» º¸´Ù ±í°Ô ÀÌÇØÇÒ ¼ö ÀÖ¾î »ý¹°ÀÇÇÐ ¿¬±¸¿Í Ä¡·á °³¹ßÀÇ ÇѰ踦 ¹Ð¾î³¾ ¼ö ÀÖ½À´Ï´Ù.

¾Ï ¿¬±¸ ºÐ¾ß¿¡¼­´Â HCSÀÇ À¯¿ë¼ºÀÌ ÀÔÁõµÇ¾ú½À´Ï´Ù. Àΰø ȯ°æ¿¡¼­ Á¾¾ç ¼¼Æ÷¸¦ ¹è¾çÇÏ´Â ÀüÅëÀûÀÎ ¸ðµ¨Àº ºÎÀÚ¿¬½º·¯¿î °Åµ¿À» ÀÏÀ¸Å³ ¼ö ÀÖ¾úÁö¸¸ HCS´Â ¼¼Æ÷ ¿Ü ¸ÅÆ®¸¯½º¸¦ Æ÷ÇÔÇϴ ȯ°æÀ» »ç¿ëÇÏ¿©ÀÌ ¹®Á¦¸¦ ÇØ°áÇÏ°íº¸´Ù ÀÚ¿¬½º·¯¿î ¼¼Æ÷ÀÇ °Åµ¿°ú ¹ÝÀÀÀ» À̲ø¾î³»°í ÀÖ½À´Ï´Ù. ÀÌ ¼Â¾÷Àº ÀÚ¿¬ Á¾¾ç ȯ°æÀ» Ãæ½ÇÇÏ°Ô ¸ð¹æÇÑ ¸¶ÀÌÅ©·Î Ƽ½´ÀÇ Á¦ÀÛÀ» °¡´ÉÇÏ°Ô Çϰí, ÀÚµ¿ Çö¹Ì°æ °Ë»ç¿Í °í±Þ È­»ó ÇØ¼®À» ÀÌ¿ëÇÏ¿© ´Ù¾çÇÑ ¾àÁ¦¿¡ ´ëÇÑ ½ÃÇèÀ» ½Ç½ÃÇÕ´Ï´Ù. ÀÌ Ç¥ÇöÇü ½ºÅ©¸®´×Àº Á¾¾ç ³»ÀÇ °³º° ¼¼Æ÷°¡ ƯÁ¤ ¾à¹°¿¡ ¾î¶»°Ô ¹ÝÀÀÇÏ´ÂÁö¸¦ È®ÀÎÇÏ°í ¾à¹° ³»¼º°ú È¿´ÉÀÇ º¯µ¿À» ¹àÇô Ä¡·á¸¦ °³º°È­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ Ä¡·á¹ýÀº ¾Ï¼¼Æ÷ÀÇ ¿ªÇп¡ ´ëÇÑ ¿ì¸®ÀÇ ÀÌÇØ¸¦ ÇöÀúÇÏ°Ô ±í°Ô Çϰí, º¸´Ù È¿°úÀûÀÌ°í ¸ÂÃã Ä¡·á ¿ä¹ýÀ» ±¸ÃàÇϴµ¥ µµ¿òÀÌ µÇ¸ç, ¾Ï Ä¡·á¿¡ Á¾Á¾ ¼ö¹ÝµÇ´Â ½ÃÇàÂø¿À¸¦ ÃÖ¼ÒÈ­ÇÕ´Ï´Ù.

±×·¯³ª, HCS¸¦ ÀÓ»óÀ¸·Î ÅëÇÕÇÏ´Â °ÍÀº ÁÖ·Î Á¤È®ÇÑ 3Â÷¿ø ¹è¾çÀÇ À¯Áö¿Í ±×¿¡ ÀÇÇØ »ý¼ºµÈ ´ë±Ô¸ð µ¥ÀÌÅÍ ¼¼Æ®ÀÇ ºÐ¼®°ú °ü·ÃµÈ º¹À⼺À¸·Î ÀÎÇØ Å« ¹®Á¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àå¾Ö¹°¿¡µµ ºÒ±¸Çϰí, ±â¼úÀÇ Áøº¸´Â ³ôÀº 󸮷® ½ºÅ©¸®´×¿¡ ÀûÇÕÇÑ Á¶Á÷-À¯»ç ±¸Á¶ÀÇ ¼ÒÇüÈ­¸¦ ÃËÁøÇÏ¿© HCS ¿ëµµÀÇ È®À强À» Çâ»ó½Ãŵ´Ï´Ù. HCSÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â ´Ù¼¼Æ÷ ¸ðµ¨°ú 3D ¸ðµ¨°úÀÇ ÅëÇÕ, À̹Ì¡ ±â¼úÀÇ ¹ßÀü, ÀÚµ¿ ºÐ¼® ¼ÒÇÁÆ®¿þ¾î °³¹ß µîÀÌ ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ¸ÂÃãÇü ÀÇ·á°¡ Á߽õǰí, ÀǾàǰÀÇ ³ë·ÂÀÌ È®´ëµÇ°í Àֱ⠶§¹®¿¡ HCS¿Í °°Àº º¸´Ù È¿°úÀûÀÎ ½ºÅ©¸®´× ±â¼úÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¹Ãø ¸ðµ¨¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú º¸´Ù ½Å¼ÓÇϰí Á¤È®ÇÑ °Ë»ç ¹æ¹ý¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼ö¿äµµ HCSÀÇ ±¤¹üÀ§ÇÑ Ã¤¿ë°ú Áö¼ÓÀûÀÎ °³¹ß¿¡ Å©°Ô ±â¿©Çϰí ÀÖÀ¸¸ç, ÀǾàǰ °³¹ß ¹× ¸ÂÃãÇü ÀÇ·á ºÐ¾ß¿¡¼­ HCSÀÇ ¿µÇâ·Â Áõ°¡¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñ 21»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global High Content Screening (HCS) Market to Reach US$2.2 Billion by 2030

The global market for High Content Screening (HCS) estimated at US$1.2 Billion in the year 2023, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2023-2030. HCS Instruments, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the HCS Consumables segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$309.7 Million While China is Forecast to Grow at 12.2% CAGR

The High Content Screening (HCS) market in the U.S. is estimated at US$309.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$492.7 Million by the year 2030 trailing a CAGR of 12.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.0% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.0% CAGR.

Global High Content Screening (HCS) Market - Key Trends and Drivers Summarized

High Content Screening (HCS) is revolutionizing the field of biological research and drug discovery by enabling detailed observations of cellular processes in real-time, particularly enhancing the development of personalized medicine. HCS utilizes advanced imaging and analysis techniques to study the effects of various compounds on cells, offering insights far beyond traditional methodologies that used isolated cells. This technique is becoming increasingly pivotal, especially with its application in living multicellular structures like organoids or tissue sections, which more accurately simulate biological interactions within organisms. This nuanced observation at the cellular level allows for a deeper understanding of the cellular dynamics that characterize health and disease states, pushing forward the boundaries of biomedical research and therapeutic development.

In the realm of cancer research, HCS has proven invaluable. Traditional models that cultivate tumor cells in artificial environments can induce unnatural behaviors; however, HCS addresses this by using environments that include an extracellular matrix, leading to more natural cellular behavior and responses. This setup allows for the creation of microtissues that closely mimic natural tumor environments, which are then tested against various drugs using automated microscopy and sophisticated image analysis. This phenotypic screening helps to personalize treatment by identifying how individual cells within a tumor respond to specific drugs, highlighting the variability in drug resistance and efficacy. This method significantly refines our understanding of cancer cell dynamics and is instrumental in crafting more effective and personalized treatment regimens, thus minimizing the trial-and-error often associated with cancer therapies.

The integration of HCS into clinical practice, however, faces significant challenges, primarily due to the complexities involved in maintaining accurate 3D cultures and the analysis of large datasets they generate. Despite these hurdles, technological advancements are facilitating the miniaturization of tissue-like structures suitable for high-throughput screening, enhancing the scalability of HCS applications. Key growth drivers for HCS include the integration with multicellular and 3D models, advancements in imaging technologies, and the development of automated analysis software. Additionally, the increasing emphasis on personalized medicine and the expansion of drug discovery efforts demand more effective screening technologies like HCS. Regulatory support for predictive models and consumer demand for quicker, more accurate testing methods also significantly contribute to the broader adoption and ongoing development of HCS, underscoring its growing impact on the fields of drug development and personalized medicine.

Select Competitors (Total 21 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â